BRPI0812729A2 - materiais e métodos para tratamento e diagnósticos de distúrbios associados com estresse oxidativo - Google Patents

materiais e métodos para tratamento e diagnósticos de distúrbios associados com estresse oxidativo

Info

Publication number
BRPI0812729A2
BRPI0812729A2 BRPI0812729-8A BRPI0812729A BRPI0812729A2 BR PI0812729 A2 BRPI0812729 A2 BR PI0812729A2 BR PI0812729 A BRPI0812729 A BR PI0812729A BR PI0812729 A2 BRPI0812729 A2 BR PI0812729A2
Authority
BR
Brazil
Prior art keywords
methods
lipoic acid
compositions
oxidative stress
treatment
Prior art date
Application number
BRPI0812729-8A
Other languages
English (en)
Inventor
Pravda Jay
Original Assignee
Pravda Jay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pravda Jay filed Critical Pravda Jay
Publication of BRPI0812729A2 publication Critical patent/BRPI0812729A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

materiais e métodos para tratamento e diagnóstico de distúrbios associados com estresse oxidativo o objeto da invenção pertence aos materiais e métodos para prevenção e tratamento de condições de doenças associadas com estresse oxidativo ou um ambiente de redução comprometido, incluindo doenças inflamatórias intestinais, tais como, doença de crohn e colite ulcerativa. um outro aspecto do objeto da invenção diz respeito a composições formuladas para administração como um enema. em uma modalidade, uma composição adequada para administração como um enema compreende uma quantidade eficaz de 5-asa e um esteróide, tal como, budesonida ou hidrocortisona. o objeto da invenção também diz respeito a composições formuladas para administração oral. em uma modalidade, a composição compreende ácido alfa-lipóico, e/ou n-acetil-l-cisteína (n-a-c), e/ou l-glutamina. o ácido alfa-lipóico pode ser ácido alfa-lipóico racêmico, ácido r-lipóico, ou ácido r-dihidro-lipóico. métodos da invenção incluem a administração de compostos ou composições da invenção. em uma modalidade, compostos ou composições da invenção são instilados retalmente em um paciente. em uma outra modalidade, compostos ou composições são administrados oralmente. o objeto da invenção também diz respeito a métodos para selecionar, avaliar risco de desenvolvimento, e/ou diagnosticar condições associadas com estresse oxidativo, tais como, colite ulcerativa e outros distúrbios inflamatórios intestinais.
BRPI0812729-8A 2007-06-13 2008-06-13 materiais e métodos para tratamento e diagnósticos de distúrbios associados com estresse oxidativo BRPI0812729A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93450507P 2007-06-13 2007-06-13
US60/934,505 2007-06-13
US6374508P 2008-02-06 2008-02-06
US61/063,745 2008-02-06
PCT/US2008/007401 WO2008156671A2 (en) 2007-06-13 2008-06-13 Materials and methods for treatment and diagnosis of disorders associated with oxidative stress

Publications (1)

Publication Number Publication Date
BRPI0812729A2 true BRPI0812729A2 (pt) 2019-02-12

Family

ID=40156844

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812729-8A BRPI0812729A2 (pt) 2007-06-13 2008-06-13 materiais e métodos para tratamento e diagnósticos de distúrbios associados com estresse oxidativo

Country Status (14)

Country Link
US (2) US8476233B2 (pt)
EP (2) EP2162125B1 (pt)
JP (1) JP2010529197A (pt)
KR (1) KR20100038098A (pt)
CN (1) CN101707877B (pt)
AT (1) ATE529105T1 (pt)
AU (1) AU2008266996A1 (pt)
BR (1) BRPI0812729A2 (pt)
CA (1) CA2691132C (pt)
IL (1) IL202685A0 (pt)
MX (1) MX2009013683A (pt)
NZ (1) NZ581710A (pt)
WO (1) WO2008156671A2 (pt)
ZA (1) ZA200908828B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
ES2882880T3 (es) * 2012-02-13 2021-12-03 Cosmo Technologies Ltd Procedimiento para tratar enfermedades intestinales que presentan al menos un componente inflamatorio
US10071058B2 (en) * 2012-03-07 2018-09-11 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
AU2013286876B2 (en) * 2012-07-03 2017-04-20 Jay Pravda Methods for treating, diagnosing and/or monitoring progression of oxo associated states
WO2014074995A1 (en) * 2012-11-09 2014-05-15 Scidose, Llc Enema composition for treatment of ulcerative colitis having long term stability
CN103622974B (zh) * 2013-12-05 2016-04-20 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法
ES2688119T3 (es) * 2015-07-08 2018-10-31 Dr. Falk Pharma Gmbh Formulación farmacéutica para el tratamiento de cambios inflamatorios del recto
US20180353447A1 (en) * 2015-11-27 2018-12-13 Birrbeheer B.V. Butyrate salts for use in inflammatory diseases
JP2019530477A (ja) * 2016-09-26 2019-10-24 プレシジョン・メディスン・ホールディングス・プロプライエタリー・リミテッド 精神分裂病および分裂情動性精神病の診断、予後、および処置
WO2018122086A1 (en) * 2016-12-28 2018-07-05 Dr. Falk Pharma Gmbh Enema for rectal application
CN108034631A (zh) * 2017-12-04 2018-05-15 武汉轻工大学 一种双氧水诱导猪小肠上皮细胞凋亡模型的建立方法
JP2019113375A (ja) * 2017-12-22 2019-07-11 サッポロホールディングス株式会社 腸内環境評価方法、大腸炎罹患リスク評価方法、及び腸内環境改善物質のスクリーニング方法
WO2019142799A1 (ja) * 2018-01-18 2019-07-25 学校法人慶應義塾 潰瘍性大腸炎治療カプセル剤
WO2024026200A1 (en) * 2022-07-27 2024-02-01 Redox Bioscience LLC Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211777A (en) * 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
JPS57500432A (pt) * 1980-03-20 1982-03-11
US4657900A (en) * 1983-09-27 1987-04-14 Rowell Laboratories Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
EP0382066A3 (de) * 1989-02-09 1992-01-08 ASTA Medica Aktiengesellschaft Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
GB8909559D0 (en) * 1989-04-26 1989-06-14 Smith Kline French Lab Pharmaceutical compositions
US5378470A (en) * 1989-07-25 1995-01-03 Henning Berlin Gmbh Rectally administered pharmaceutical preparation
EP0427247B1 (de) * 1989-11-09 1998-03-11 ASTA Medica Aktiengesellschaft Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
DE4218572A1 (de) 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
US6444221B1 (en) * 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
JP2917799B2 (ja) * 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
US5563131A (en) * 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
DE19509806A1 (de) * 1995-03-21 1996-09-26 Basf Ag Lagerstabile Arzneiformen
US5817630A (en) * 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
US6197749B1 (en) * 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
US6262019B1 (en) * 1998-04-30 2001-07-17 Vit-Immune, L. C. Method of treatment of glutathione deficient mammals
CA2274943A1 (en) * 1998-06-17 1999-12-17 Stephen L. Wolman Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof
AR042572A1 (es) 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
EP1172110A3 (de) * 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
US20030119797A1 (en) * 2001-05-09 2003-06-26 Salah-Dine Chibout Methods for selective immunomodulation
US20030235571A1 (en) * 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US7195766B2 (en) * 2002-09-10 2007-03-27 National Jewish Medical And Research Center Product and process for liquefaction of mucus or sputum
US7157444B2 (en) * 2002-12-21 2007-01-02 Deanna Jean Nelson Aminosalicylate derivatives for treatment of inflammatory bowel disease
DE10305661A1 (de) 2003-02-12 2004-08-26 Degussa Ag Darreichungsform zur Kolon-spezifischen Wirkstofffreisetzung
WO2004078172A2 (en) * 2003-03-06 2004-09-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sod mimic multifunctional compounds for treating inflammatory bowel disease
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress

Also Published As

Publication number Publication date
CA2691132A1 (en) 2008-12-24
EP2162125A2 (en) 2010-03-17
EP2162125A4 (en) 2010-08-25
WO2008156671A2 (en) 2008-12-24
ZA200908828B (en) 2010-12-29
KR20100038098A (ko) 2010-04-12
CN101707877B (zh) 2013-01-09
NZ581710A (en) 2012-02-24
ATE529105T1 (de) 2011-11-15
IL202685A0 (en) 2010-06-30
EP2392321A1 (en) 2011-12-07
CN101707877A (zh) 2010-05-12
US8476233B2 (en) 2013-07-02
EP2162125B1 (en) 2011-10-19
MX2009013683A (es) 2010-04-07
US20130344184A1 (en) 2013-12-26
JP2010529197A (ja) 2010-08-26
CA2691132C (en) 2016-01-12
AU2008266996A1 (en) 2008-12-24
WO2008156671A3 (en) 2009-03-12
US20100184728A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
BRPI0812729A2 (pt) materiais e métodos para tratamento e diagnósticos de distúrbios associados com estresse oxidativo
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
HRP20171024T1 (hr) Novi spoj, koristan u liječenju degenerativnih i upalnih bolesti
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
Zhao et al. Hydrogen sulfide improves colonic barrier integrity in DSS-induced inflammation in Caco-2 cells and mice
GEP20156281B (en) Orally administered corticosteroid compositions
WO2005072113A3 (en) Compositions and methods of treatment for inflammatory diseases
NO20084199L (no) Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom
WO2011011882A8 (en) Hydroxy fatty acid compounds and uses thereof for disease treatment and diagnosis
MX2010000224A (es) Mejoramiento de la memoria en individuos con mini-examen de estado mental de 24-26.
BRPI0712322A2 (pt) compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
WO2010039529A3 (en) Compositions and methods for the treament of inflammatory disease
Friedman et al. Cleft palate, retrognathia and congenital heart disease in velo-cardio-facial syndrome: a phenotype correlation study
UA110463C2 (ru) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
NO20091182L (no) 2-fenoksypyrimidinonanaloger
Azim et al. Effects of agomelatine on pentylenetetrazole-induced kindling, kindling-associated oxidative stress, and behavioral despair in mice and modulation of its actions by luzindole and 1-(m-chlorophenyl) piperazine
NO20076405L (no) Anvendelse av 24-nor-UDCA
AU2010212350A1 (en) Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
MX2008011473A (es) El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica.
BRPI0408274A (pt) compostos de ligação de amilóide, composição farmacêutica e método de detecção de depósito de amilóide in vivo
MX2009000763A (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina.
WO2007121545A8 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
Tuncdemır et al. The relationship between plasma MicroRNAs and serum mercury levels in patients with amalgam filling and dentists

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2515 DE 19-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]